It was March 2010 when Pfizer first lost its bid to escape a $142 million racketeering verdict, with a federal jury ruling the company's marketing of epilepsy treatment Neurontin violated both federal and state law. Now, nearly four years later, Pfizer's appeal process has come to the end of the line. The Supreme Court has refused to hear the drugmaker's appeal, leaving the verdict intact and the door open for similar claims to proceed.
Six whistleblowers are collecting some serious dough for helping the U.S. Department of Justice tag Johnson & Johnson with off-label marketing. Under the False Claims Act, they're due a percentage of the $2.2 billion settlement, and in this case, that's more than $20 million each.
Doctors and patients have been waiting impatiently for the big FDA approval on Friday: Gilead Sciences' breakthrough hepatitis C treatment sofosbuvir, now dubbed Sovaldi. But so have some of Gilead's fiercest critics, and those groups came out swinging.
The Department of Health and Human Services has just added United Therapeutics to the growing list of companies under scrutiny for their marketing practices, calling into question three of its pulmonary arterial hypertension drugs--the only three products it sells.
Japanese drugmaker Eisai is cutting its R&D operations, with plans to eliminate 130 positions from its facility in Andover, MA, as well as other research centers around the world.
GlaxoSmithKline CEO Andrew Witty is on his first trip to China since authorities there alleged his company funneled $490 million in bribes to doctors. Despite the scandal, GSK says it remains committed to doing business in China.
A new study in JAMA Pediatrics finds that sex and money each play a role in U.S. parents' reluctance to vaccinate their children against the human papillomavirus. But a lack of easy-to-understand information about the shots--and often, the lack of a doctor's clear recommendation for them--are also helping to depress vaccination rates.
Carrying out a $1 billion cost-cutting program is easier if you're a stranger. That's the view of Takeda Pharmaceutical CFO François-Xavier Roger, who stepped into his role in September and took up the mantle of efficiency czar.
Pfizer, which sells the hemophilia drug Xyntha, last year rolled out its HemMobile app to build its relationship with patients who use its treatments. The fact that Pfizer didn't include a version for the BlackBerry goes a long way to explaining why the drug giant is asking its own remaining Blackberry users to turn in those phones.
Another cancer drug approval, another nosebleed-level price. Johnson & Johnson and Pharmacyclics' breakthrough drug Imbruvica (ibrutinib) won FDA approval yesterday for a rare form of lymphoma. Soon after, the companies said Imbruvica would be priced at more than $90 per pill. At four pills per day, that's about $130,000 per year.